Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Pharmaceutical
According to a report from industry analyst DelveInsight, the market for Down syndrome treatments in the USA is now valued at almost $250 million. 27 November 2024
Pharmaceutical
The European Commission (EC) has approved a single-vial, fully liquid presentation of Menveo (meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y, UK pharma major GSK announced today. 27 November 2024
Pharmaceutical
The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA. 27 November 2024
Pharmaceutical
Novartis announced today that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) at high risk of recurrence. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Pharmaceutical
The Biden administration has proposed a new rule that could significantly expand Medicare and Medicaid coverage for obesity medications, potentially benefiting millions of Americans. 27 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has extended the review period for Soleno Therapeutics’ the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Pharmaceutical
Swiss drugmaker Idorsia was trading more than 10% higher by lunchtime on Wednesday. Idorsia earlier announced that it has entered into exclusive negotiations with an undisclosed party for the global rights to aprocitentan. 27 November 2024
Biosimilars
Samsung Bioepis has appointed Kyung-Ah Kim as its new president and chief executive, succeeding Christopher Hansung Ko, who will lead the Samsung Future Business Division. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Pharmaceutical
Japanese drugmaker Otsuka has announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for the manufacture and sale in Japan of bempedoic acid - trade name Nexletol in Japan - for the treatment of hypercholesterolemia and familial hypercholesterolemia. 27 November 2024
Pharmaceutical
Berlin, Germany-based Eckert & Ziegler Radiopharma has received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand, by the European Commission (EC). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Pharmaceutical
US central nervous system (CNS) disorders specialist Axsome Therapeutics today released encouraging late-stage results for its narcolepsy candidate AXS-12 (reboxetine), sending its shares edging up 2.6% to $100.00 in pre-market activity. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
All news
Biotechnology
Japanese drug major Astellas Pharma today announced positive top-line results from the Phase III SPOTLIGHT clinical trial evaluating the efficacy and safety of zolbetuximab in combination with mFOLFOX6 (a combination regimen that includes oxaliplatin, leucovorin and fluorouracil). 17 November 2022
Biotechnology
Germany’s Merck KGaA has announced an investment of more than 290 million euros ($302 million) in its biosafety testing capacity at Rockville, Maryland, USA. 16 November 2022
Pharmaceutical
Due to the high-risk nature of drugs being developed for neurology diseases, most product launches in the recent history of Parkinson’s disease have been the result of strategic partnerships for marketing and sales, with few exceptions. 16 November 2022
Biotechnology
Marking a second M&A deal this year, USA-based gene therapy company Kriya Therapeutics today announced the acquisition of a privately held biotechnology company Redpin Therapeutics, which is developing regulatable gene therapies for intractable diseases of the nervous system. 16 November 2022
Biotechnology
Bonum Therapeutics, a biopharma using allosteric regulation to create conditionally active and less toxic medicines, has announced a $93 million Series A financing. 16 November 2022
Biosimilars
Access to therapies used to treat major chronic diseases remains particularly limited in Central and Eastern Europe (CEE). Off patent medicines are often the first opportunity for patients to access the essential medicines they need, says Medicines for Europe, the trade body representing bakers of biosimilar and generic drugs. 16 November 2022
Biotechnology
In a draft recommendation, the UK’s reimbursement agency has found in favor of three COVID-19 treatments, while sidelining several others. 16 November 2022
Pharmaceutical
Cambridge, UK-based Napp Pharmaceuticals today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted a marketing authorization application for rezafungin, a novel echinocandin in clinical development for the treatment of invasive candidiasis in adult patients. 16 November 2022
Biotechnology
Positive top-line results from a trial in atopic dermatitis (AD) lifted shares in Californian biotech Arcutis Biotherapeutics around 4% on Tuesday. 16 November 2022
Biotechnology
Swiss biotech Idorsia has entered into an exclusive licensing agreement with China’s Simcere Pharmaceutical for the commercialization of its dual orexin receptor antagonist daridorexant, a treatment for adult patients with insomnia, in China. 16 November 2022
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday issued a Federal Register notice, Safety and Effectiveness of Certain Naloxone Hydrochloride Drug Products for Nonprescription Use, that may help facilitate the development and approval of certain non-prescription naloxone drug products, including through the switch of certain naloxone drug products from prescription status to non-prescription status. 16 November 2022
Biotechnology
A think tank report has been published ahead of the UK government’s autumn statement, calling for a reform of R&D tax credits. 15 November 2022
Biotechnology
Boston, USA-based biotech start-up Jnana Therapeutics, which is leveraging its next-gen chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced two important milestones for the company. 15 November 2022
Biotechnology
Moderna has announced that both of its bivalent Omicron-targeting booster candidates trigger a superior antibody response compared to a booster of mRNA-1273, the firm's prototype vaccine, against Omicron, in Phase II/III trials. 15 November 2022
Biotechnology
Japanese drugmaker Daiichi Sankyo edged up 1.7% to 4,486 yen today, as it announced that a trial evaluating the efficacy and safety of booster vaccination with DS-5670, an mRNA vaccine against the novel coronavirus infectious disease (COVID-19), the primary endpoint was achieved. 15 November 2022
Pharmaceutical
Clinical-stage biopharma company Satsuma Pharmaceuticals on Monday revealed that its experimental lead treatment for acute migraine headaches failed to meet the main goals of a late-stage trial, sending its shares plunging 83% to $0.68. 15 November 2022
Biotechnology
The US Food and Drug Administration (FDA) yesterday granted accelerated approval for ImmunoGen’s Elahere (mirvetuximab soravtansine-gynx) for adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. 15 November 2022
Pharmaceutical
Japanese drugmaker Ono Pharmaceutical and Poland’s Captor Therapeutics, a specialist in the development of targeted protein degradation (TPD)-based drugs, have entered a worldwide drug discovery collaboration. 15 November 2022
Pharmaceutical
A new kind of pain medicine has performed well in a Phase II trial, according to data presented at the 16th Annual Pain Therapeutics Summit in Washington DC, USA. 15 November 2022
Generics
As Indian drugmakers cry foul on not receiving an appropriate "incentive for incremental innovation," the government and the domestic pharmaceutical industry are to sit together to iron out the kinks on a pricing mechanism for drugs that are going off patent, reports The Pharma Letter’s India correspondent. 15 November 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze